Therefore, the combination of NO blockers and ICIs could cause more T-cells to enter the tumour, where they in turn are not inhibited by PD-1-stimulation, thus improving the treatment of MCC. The gene discussed is PDCD1; the disease is Merkel cell skin cancer.